

1 **Tissue-specific Genome Editing *in vivo***

2 **by MicroRNA-repressible Anti-CRISPR Proteins**

3

4 Jooyoung Lee^a, Haiwei Mou^{a,c}, Raed Ibraheim^a, Shun-Qing Liang^a,
5 Wen Xue^{a*}, Erik Sontheimer^{a,b*}

6

7 ^aRNA Therapeutics Institute

8 ^bProgram in Molecular Medicine

9 University of Massachusetts Medical School
10 Worcester, Massachusetts, U.S.A.
11

12 ^cCurrent address: 1 Bungtown Road, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724
13

14

15

16 Correspondence: wen.xue@umassmed.edu, erik.sontheimer@umassmed.edu

17

18 Running title: Control of Cas9 by miRNA-regulated anti-CRISPRs

19

20 Key words: Cas9, anti-CRISPR, microRNA, tissue-specific editing

21

22

23 **Abstract**

24 CRISPR-Cas systems are bacterial adaptive immune pathways that have revolutionized biotechnology
25 and biomedical applications. Despite the potential for human therapeutic development, there are many
26 hurdles that must be overcome before its use in clinical settings. Some clinical safety concerns arise from
27 persistent activity of Cas9 after the desired editing is complete, or from editing activity in unintended cell
28 types or tissues upon *in vivo* delivery [e.g. by adeno-associated viruses (AAV)]. Although tissue-specific
29 promoters and serotypes with tissue tropisms can be used, suitably compact promoters are not always
30 available for desired cell types, and AAV tissue tropisms are not absolute. To reinforce tissue-specific
31 editing, we exploited anti-CRISPR proteins (Acrs), which are proteins evolved as countermeasures against
32 CRISPR immunity. To inhibit Cas9 in all ancillary tissues without compromising editing in the target
33 tissue, we established a flexible platform in which an *Acr* transgene is repressed by endogenous, tissue-
34 specific microRNAs (miRNAs). We demonstrate that miRNAs regulate the expression of an *Acr* transgene
35 bearing miRNA-binding sites in its 3' UTR, and control subsequent genome editing outcomes in a cell-
36 type specific manner. We also show that the strategy is applicable to multiple Cas9 orthologs and their
37 respective Acrs. Furthermore, we demonstrate that *in vivo* delivery of Cas9 and Acrs that are targeted for
38 repression by liver-specific miR-122 allow editing in the liver while Acrs devoid of miRNA regulation
39 prevent Cas9 activity. This strategy provides additional safeguards against off-tissue genome editing by
40 confining Cas9 activity to selected cell types.

41

42 **Introduction**

43 Clustered, regularly interspaced, short, palindromic repeats (CRISPR) and CRISPR-associated (*cas*) genes
44 comprise prokaryotic adaptive immune defense systems that are classified into two major classes and
45 multiple types and subtypes (e.g. II-A, -B, and -C) (Makarova *et al.* 2018). Cas9s are monomeric effector
46 proteins in type II systems that can target nearly any DNA sequence when guided by a CRISPR RNA
47 (crRNA) base paired with a trans-activating RNA (tracrRNA), or as a fused form of both RNAs known as
48 single guide RNA (sgRNA) (Deltcheva *et al.* 2011; Garneau *et al.* 2010; Jinek *et al.* 2012). The robustness

49 and ease of Cas9 programmability have greatly facilitated its rapid adoption in genome editing and
50 modulation (Komor et al. 2017). As medical, agricultural, and environmental technologies advance, safety
51 concerns must be considered and addressed, especially with potential human therapeutics. *In vivo*
52 therapeutics will often require not only precise editing at the intended genomic site but also in the
53 intended tissue, given the possible risks of unwanted double-strand break (DSB) induction. For example,
54 Cas9-induced DSBs can elicit translocations that can be associated with heritable disorders or various
55 kinds of cancer, or large deletions and other rearrangements (Jiang et al. 2016; Maddalo et al. 2014;
56 Kosicki et al. 2018). Moreover, some delivery modalities such as viral vectors are likely to affect many cell
57 types and tissues beyond the intended therapeutic target (Hinderer et al. 2018). AAV is currently the most
58 widely used transgene delivery vector for therapeutic applications in preclinical and clinical settings.
59 Different AAV serotypes have some tissue tropism, however, they can still infect broad ranges of tissues *in*
60 *vivo* (Gao et al. 2004). Although tissue-specific promoters can be used to drive transgene expression in
61 particular cell types (Walther and Stein 1996), some target tissues lack promoters that are sufficiently
62 active, specific, or small for AAV deployment. These limitations necessitate the development of new
63 regulatory strategies to enforce tissue specificity for *in vivo* applications.

64

65 Although several means of regulating genome editing activities have been reported, a prominent recent
66 advance has resulted from the discovery of anti-CRISPR (Acr) proteins (Bondy-Denomy et al. 2013). Acrs
67 are small proteins encoded by bacteriophages and other mobile genetic elements that have evolved as
68 natural countermeasures against CRISPR-Cas immunity. Type II Acrs targeting Cas9 orthologs (Pawluk
69 et al. 2016; Rauch et al. 2017; Hynes et al. 2017, 2018), as well as the recently-discovered type V Acrs
70 targeting Cas12a (Watters et al. 2018; Marino et al. 2018), are of particular interest because they can
71 potentially provide temporal, spatial, or conditional control over established genome editing systems.
72 Applications of Acrs have been demonstrated in bacteria (Marshall et al. 2018; Rauch et al. 2017), in
73 yeasts to inhibit gene drives (Goeckel et al. 2019), and in mammalian cells to modulate genome editing,

74 dCas9-based imaging, epigenetic modification, and genetic circuits (Pawluk et al. 2016; Rauch et al. 2017;
75 Shin et al. 2017; Bubeck et al. 2018; Liu et al. 2018; Nakamura et al. 2019).

76

77 To improve current technologies that regulate the tissue specificity of editing, we have developed an Acr-
78 based approach to inhibit Cas9 in all ancillary tissues while allowing editing in the target tissue. To
79 spatially regulate Acr expression, we exploited endogenous tissue-specific microRNAs (miRNAs) to
80 repress Acr expression in the target tissue. MiRNAs are a class of small regulatory RNAs whose
81 mechanisms of messenger RNA (mRNA) regulation are extensively studied (Jonas and Izaurralde 2015).
82 These RNAs load into an argonaute protein (e.g. Ago2) to form RNA-induced silencing complexes
83 (RISCs) that recognize complementary sequences present in mRNA targets, leading to translational
84 repression and mRNA destabilization (Bartel 2018). In mammalian cells, Ago2-loaded miRNAs can
85 subject extensively or perfectly complementary mRNA targets to endonucleolytic cleavage, enabling
86 strong downregulation. Since miRNA response elements (MREs) are very small (~22 nucleotides or less),
87 this regulatory modality places minimal burden on AAV vector capacity, which is limited to ~4.8 kb.
88 Moreover, large numbers of mammalian cell and tissue types express specific combinations of tissue-
89 restricted miRNAs (Lagos-Quintana et al. 2002).

90

91 Here we establish a flexible platform in which an *Acr* transgene is repressed by endogenous, tissue-specific
92 miRNAs to control Acr expression spatially. We demonstrate that miRNAs can regulate the expression of
93 an *Acr* transgene bearing miRNA-binding sites in its 3' untranslated region (UTR) and control subsequent
94 genome editing outcomes in a cell-type specific manner. We also show that the strategy is applicable to
95 multiple Cas9 orthologs and their respective Acrs, including the widely-used *Streptococcus pyogenes* (SpyCas9)
96 (Cong et al. 2013; Mali et al. 2013; Jinek et al. 2013; Cho et al. 2013; Hwang et al. 2013) as well as the
97 more readily AAV-deliverable Cas9 orthologs from *Neisseria meningitidis* (Nme1Cas9 and Nme2Cas9)
98 (Ibraheim et al. 2018; Edraki et al. 2018). Furthermore, we have expressed anti-CRISPR proteins in mice
99 to achieve efficient inhibition of Cas9-mediated genome editing *in vivo* without detectable toxicity. We

100 show that co-delivery of Cas9, guide RNA, and miR-122-repressible Acr transgenes allow editing in the
101 liver (the only tissue where miR-122 is expressed), while an otherwise identical Acr transgene that lacks
102 any miR-122 MREs effectively prevent Cas9 activity. This strategy establishes the *in vivo* efficacy of Acrs
103 in mammals and provides the basis for restriction of undesired off-tissue editing by confining Cas9 activity
104 to selected cell types.

105

106 **Results**

107

108 **AAV delivery of all-in-one Nme1Cas9/sgRNA results in editing in various tissues**

109 Previously, our group has used all-in-one AAV8 to deliver a human-codon-optimized Nme1Cas9 for
110 genome editing *in vivo* (Ibraheim et al. 2018). Nme1Cas9 is smaller and less prone to off-target editing
111 than the widely used SpyCas9 (Amrani et al. 2018). Upon delivery of all-in-one rAAV8 viruses expressing
112 hNme1Cas9 driven by a ubiquitous U1a promoter and sgRNA via tail vein injection, we observed high
113 editing efficiency in liver tissues collected 50 days post-injection (Ibraheim et al. 2018). To gauge editing
114 efficiencies in non-target tissues outside of the liver, tissues from cardiac and skeletal muscle
115 (gastrocnemius muscle) as well as kidney and brain were collected and analyzed (Supplemental Fig. 1).
116 Although lower than the editing observed in liver tissues ($51.33 \pm 4.93\%$), appreciable indel frequencies
117 were observed in different organs, especially in the heart ($22.33 \pm 3.79\%$) (Supplemental Fig. 1). This is
118 consistent with previous reports that AAV8 effectively transduces mouse hepatocytes but also infects
119 skeletal and cardiac muscles (Nakai et al. 2005) as well as brain at high doses (Zincarelli et al. 2008).
120 These observations, along with the known multi-tissue tropisms of other AAV serotypes (Zincarelli et al.
121 2008), underscore the potential benefit of using miRNA-repressible *Acr* transgenes to reinforce tissue-
122 specific editing.

123

124 **A strategy for microRNA-regulated anti-CRISPR proteins**

125 Endogenous miRNA-mediated post-transcriptional gene silencing has proven to be an effective and
126 tissue-specific approach to regulate transgene expression upon AAV delivery *in vivo* (Xie et al. 2011).
127 Delivery of Cas9/sgRNA via AAV has the potential to induce editing in multiple transduced tissues (e.g.
128 heart, skeletal muscles etc.); however, co-delivery of the miRNA-repressible Acr will inhibit editing in such
129 non-target tissues due to the latter's lack of tissue-specific miRNAs (and therefore their inability to silence
130 the expression of the Acr inhibitor). In the case of the liver-specific miRNA miR-122, in the target tissue
131 the *Acr* gene with miR-122 MREs will be repressed, enabling Cas9-mediated editing (Fig. 1A). In contrast,
132 off-tissue editing (e.g. in cardiac and skeletal muscle, Supplemental Fig. 1) will be inhibited by the Acr,
133 since those extrahepatic tissues lack miR-122 and therefore fail to silence Acr expression. To validate this
134 concept, we chose two well-established Cas9-Acr combinations: AcrIIC3_{Nme} and Nme1Cas9/Nme2Cas9
135 (Type II-C; (Pawluk et al. 2016; Edraki et al. 2018)) as well as AcrIIA4_{Lmo} and SpyCas9 (Type II-A;
136 (Rauch et al. 2017)). Nme2Cas9 is a recently reported Cas9 ortholog that has a dinucleotide (N₄CC)
137 protospacer adjacent motif (PAM) (Edraki et al. 2018), enabling a target site density comparable to that of
138 SpyCas9 (NGG PAM). A type II-C Nme1Cas9/Nme2Cas9 inhibitor, AcrIIC3_{Nme}, limits target DNA
139 affinity (Harrington et al. 2017; Zhu et al. 2019). AcrIIA4_{Lmo} inhibits the widely-used SpyCas9 and also
140 prevents DNA binding, in this case by occluding the PAM-binding cleft (Rauch et al. 2017; Dong et al.
141 2017; Shin et al. 2017; Yang and Patel 2017). For our *in vitro* validations, both Cas9 and Acr expression
142 vectors were driven by the cytomegalovirus (CMV) promoter. We generated codon-optimized Acr
143 expression vectors identical in every respect except for the presence or absence of MREs in the 3' UTR
144 (Supplemental Table 1). Since miR-122 is a well-validated miRNA that is highly expressed specifically in
145 hepatic cells, we decided to validate the concept using this miRNA. We placed three tandem miR-122
146 binding sites (3xmiR122BS) in the 3' UTR of each *Acr* gene, which also included a C-terminal mCherry
147 fusion to enable expression to be detected by fluorescence microscopy or flow cytometry (Fig. 1B). Fusion
148 of heterologous domains do not compromise the inhibitory potency of these Acrs (Goeckel et al. 2019;
149 Nakamura et al. 2019).

150

151 **Validation of microRNA-repressible anti-CRISPR expression vectors**

152 We used a human hepatocellular carcinoma cell line (Huh-7) that abundantly expresses miR-122, in
153 contrast to non-hepatic cell lines such as human embryonic kidney (HEK293T) cells (Fukuhara et al.
154 2012). As an initial test of miR-122 repression of Acr expression, we transfected cells with plasmids
155 expressing AcrIIC3-FLAG-mCherry-3xmiR122BS, AcrIIA4-FLAG-mCherry-3xmiR122BS, or their
156 respective control vectors lacking the miR-122 binding sites (Fig. 1B). A separate GFP expression plasmid
157 was also included to indicate transfection efficiencies in each cell line. When these vectors were transiently
158 transfected, the expression of mCherry-fused Acr with miR-122 MREs was dramatically suppressed in
159 Huh7 cells whereas Acr-mCherry lacking 3xmiR122BS was still well expressed (Fig. 2A). In HEK293T
160 cells, there was no discernible difference in mCherry signal from the Acr and Acr-3xmiR122BS constructs
161 based on both fluorescence microscopy and flow cytometry (Fig. 2B). Acr expression was also confirmed
162 by anti-FLAG western blot analysis (Fig. 2). Compared to HEK293T cells, transfection efficiency was
163 lower in Huh-7 cells as indicated by a decrease in overall GFP and mCherry signals (Fig. 2A).
164 Nevertheless, fluorescence microscopy, flow cytometry, and Western blot analysis consistently revealed
165 effective reductions of both AcrIIC3-3xmiR122BS and AcrIIA4-3xmiR122BS expression in Huh-7, but
166 not in HEK293T cells. Expression of Acrs lacking miR-122 MREs was unaffected in both cell lines,
167 consistent with effective regulation of Acr by miR-122 only in hepatic cells.

168

169 **MicroRNA repression enables escape from anti-CRISPR inhibition during genome editing
170 in hepatocytes**

171 Having demonstrated that anti-CRISPR repression in hepatocyte-derived cells can be conferred by miR-
172 122 MREs, we then tested whether this repression is sufficient to allow genome editing by Cas9 orthologs
173 (SpyCas9, Nme1Cas9 and Nme2Cas9). We transiently transfected separate expression plasmids for Cas9,
174 a cognate sgRNA, and an Acr, with the latter construct either including or omitting miR-122 binding
175 sites. We chose validated, endogenous sites in the human genome for each Cas9 ortholog (Fig. 3): the

176 Nme1Cas9 target site NTS33 in the *VEGFA* gene (Fig. 3A), the Nme2Cas9 target site TS6 in the
177 *LINC01588* gene (Fig. 3B), and the SpyCas9 target site 1617 in the *BCL11A* enhancer (Fig. 3C) (Amrani et
178 al. 2018; Edraki et al. 2018; Wu et al. 2019). In HEK293T cells, AcrIIC3_{Nme} and AcrIIA4_{Lmo} robustly
179 inhibited genome editing by Nme1/2Cas9 and SpyCas9, respectively, as expected (Pawluk et al. 2016;
180 Rauch et al. 2017) (Fig. 3). The presence or absence of miR-122 MREs had no significant effect on
181 editing inhibition in this non-miR-122-expressing cell type. Although the editing efficiency was variable
182 among Cas9 orthologs at these target sites, and although transfection efficiencies were reduced in Huh-7
183 cells, AcrIIC3_{Nme} and AcrIIA4_{Lmo} also prevented editing in this cell type when expressed from constructs
184 that lack miR-122 MREs. By contrast, Acrs plasmids that incorporated miR-122 MREs in the 3'UTRs
185 failed to inhibit Cas9 editing in Huh-7 cells, as indicated by editing efficiencies that were similar to the no-
186 Acr control (Fig. 3). This trend was true for all three Cas9 orthologs tested.

187

188 **MiR-122-dependent *in vivo* genome editing conferred by an anti-CRISPR protein**

189 For our *in vivo* tests we focused on Nme2Cas9, due to its compact size, high target site density, and relative
190 lack of off-target editing, all of which are advantageous for therapeutic development. We used a
191 previously validated all-in-one AAV vector that expresses Nme2Cas9 from the minimal U1a promoter, as
192 well as a U6 promoter-driven sgRNA targeting *Rosa26* (Ibraheim et al. 2018; Edraki et al. 2018) (Fig. 4A).
193 We also generated AcrIIC3_{Nme} expression plasmids driven by the strong CB-PI promoter and associated
194 expression elements; in addition, these AcrIIC3_{Nme} constructs either included or omitted the three tandem
195 miR-122 MREs in the 3' UTR (Fig. 4A). For *in vivo* delivery we used hydrodynamic injection, which is a
196 non-viral method of transient hepatocyte transfection that allows expression from naked DNA plasmids
197 (Zhang et al. 1999). This injection method delivers DNA to ~20% of hepatocytes for transient expression
198 and has minimal transgene expression in organs other than the liver. Since miR-122 is abundant in the
199 liver, and because Cas9 delivered to the liver by hydrodynamic injection can induce editing (Xue et al.
200 2014), this experimental approach enables tests of liver-specific editing (and inhibition of editing) in the
201 presence or absence of Acr expression. Plasmids were injected into adult, wild-type C57BL/6 mice via tail

202 vein and liver tissues were collected at 7 days post-injection (Fig. 4B). To determine the effective dose of
203 Acr plasmid needed to inhibit Nme2Cas9 editing *in vivo*, we co-injected varying Cas9:Acr plasmid ratios
204 (1:1, 1:1.5, and 1:2). AcrIIC3_{Nme} efficiently inhibited Nme2Cas9 editing at all ratios tested (Fig. 4C). No
205 apparent liver damage was detected in the liver tissues following staining with haemotoxylin and eosin
206 (H&E) (Supplemental Fig. 2). Once we defined the necessary plasmid dose, we subjected three groups of
207 mice to hydrodynamic injection with plasmid combinations that included Nme2Cas9 with (i) no Acr, (ii)
208 AcrIIC3_{Nme}, and (iii) AcrIIC3_{Nme}-3xmiR122BS (Fig. 4A). In the livers of mice receiving no Acr, Nme2Cas9
209 yielded a mean editing efficiency of $4.2 \pm 0.6\%$ ($n = 6$ mice), similar to levels seen previously with this and
210 other Cas9 orthologs upon hydrodynamic injection (Ibraheim *et al.* 2018; Xue *et al.* 2014). As expected,
211 co-injection of AcrIIC3_{Nme} plasmid strongly reduced the editing efficiency to $1 \pm 0.5\%$ ($P = 0.0025$). By
212 contrast, AcrIIC3_{Nme}-3xmiR122BS failed to inhibit Nme2Cas9 editing, with the indel efficiency
213 comparable to no Acr group ($6.7 \pm 1.1\%$, Fig. 4D). We confirmed the expression of Nme2Cas9 in all three
214 groups by immunohistochemistry (IHC) against the 3xHA epitope (Supplemental Fig. 3). We were unable
215 to detect AcrIIC3_{Nme} by IHC against the FLAG epitope in mice injected with AcrIIC3_{Nme}. It is possible that
216 1xFLAG tag is too weak for IHC detection. However, we ruled out the possibility of injection failures by
217 including control plasmids in our experiment. Specifically, we co-injected additional plasmids encoding a
218 Sleeping Beauty transposon system (Ivics *et al.* 1997) that integrates an mCherry expression cassette into
219 the mouse genome to report on the success of plasmid injection. In all three groups of injected mice, we
220 observed mCherry expression in liver tissue sections from injected mice by IHC (Supplemental Fig. 3),
221 confirming successful liver transfection. In summary, consistent with our results in human Huh-7 cells,
222 endogenous miR-122 in mouse hepatocytes *in vivo* can be exploited to repress Acr expression, and
223 therefore allow tissue-specific Cas9 genome editing, in liver tissues.

224

225 **Discussion**

226

227 Although CRISPR-Cas9 technologies have immense promise in numerous aspects of biomedical science,
228 many applications will benefit from tight temporal or spatial control over Cas9 activity, especially in the
229 context of clinical development. Confining Cas9 activity to target cells and tissues of interest is highly
230 desirable to prevent unforeseen adverse effects associated with off-tissue and off-target editing *in vivo*.
231 Natural inhibitors of Cas proteins, anti-CRISPRs, can be repurposed as tools to limit the potential for
232 unwanted edits. Acrs have several potential advantages for implementation as regulators. They are
233 natural and genetically encodable inhibitors of Cas nucleases that have evolved as powerful inactivators of
234 CRISPR immunity, usually offering some degree of specificity for particular types of systems. Moreover,
235 their inhibition is often tunable/titratable based on the relative expression levels of Acrs and the target
236 effectors, based upon stoichiometric mechanisms of action for most of them (van Gent and Gack 2018;
237 Bondy-Denomy 2018). Most Acrs are small proteins that can tolerate fusions of fluorescent proteins or
238 epitope tags, which could make them convenient for *in vivo* delivery by viral vectors or mRNAs and
239 detection by fluorescence.

240
241 Here, we present a proof-of-concept demonstration of anti-CRISPR regulation by endogenous miRNAs
242 *in vivo*, yielding tissue-specific control over CRISPR-Cas9 editing. We demonstrated that miRNA-
243 mediated inhibition of anti-CRISPRs bearing hepatocyte-specific miR-122 MREs allows genome editing
244 in a human hepatocyte cell line, Huh-7. Although this study used AcrIIC3_{Nme} for type II-C Nme1Cas9
245 and Nme2Cas9, as well as AcrIIC4_{Lmo} for SpyCas9, any well-validated combination of Acr-Cas nuclease
246 will be compatible with this strategy, making it a versatile platform. With the wealth of new Acrs
247 emerging for different CRISPR effectors (e.g. Cas12a; (Watters *et al.* 2018; Marino *et al.* 2018), we expect
248 that opportunities for implementing this strategy will continue to increase. We also note that expression
249 profiles of many miRNAs are well-defined for many tissues at many developmental stages and in
250 numerous disease states (Alvarez-Garcia and Miska 2005). For example, miR-1 is highly and specifically
251 expressed in cardiac and skeletal muscle tissues (Horak *et al.* 2016). The miRNA-repressible Acr system
252 affords great flexibility in changing editing tissue specificity, given the ease with which the MREs can be

253 swapped in the 3'UTR of the Acr transcript. Furthermore, because MREs are so small, this approach is
254 well suited for viral modes of delivery (given the genome capacity constraints of viral vectors), and could
255 confer specificity for some tissues that lack vector-compatible, tissue-specific promoters.

256

257 We extend this strategy to animal studies that document anti-CRISPR efficacy during Cas9-mediated
258 editing *in vivo*. To our knowledge, this is the first demonstration of *in vivo* expression of Acr proteins in
259 vertebrate models to inhibit Cas9 editing activity. From this study, we did not observe overt toxicity in the
260 transfected liver tissues, although the safety and immunity profiles of delivered Acr proteins will need to
261 be examined over longer periods of time and in additional biological contexts.

262

263 We exploited endogenous miRNAs for spatial control of anti-CRISPR expression to achieve tissue-
264 specific editing by Cas9 *in vivo*. The endogenous miRNA repertoire has been combined with the CRISPR-
265 Cas machinery previously to regulate the expression of Cas9 itself (Hirosawa *et al.* 2017; Senís *et al.* 2014).
266 Whereas detargeting Cas9 expression from the liver (e.g. with miR-122) will allow editing to occur
267 everywhere except the liver, our strategy will restrict Cas9 activity to the liver itself and protect all the
268 other tissues. This will be particularly useful to restrict Cas9 genome editing to a single desired tissue
269 following a systemic Cas9 delivery by AAV. Our results complement a strategy described by Wang *et al.*,
270 which exploits miRNAs to release sgRNAs from longer, inactive precursors (Wang *et al.* 2019), though
271 this approach has not yet been validated in tissue-specific editing applications *in vivo*. While this
272 manuscript was in preparation, Hoffman *et al.* also reported using miRNA-regulated Acr proteins to
273 achieve cell-type specific editing in hepatocytes and myocytes in culture (Hoffmann *et al.* 2019). Our
274 studies further demonstrate that miRNA-repressible anti-CRISPRs can be applied in the tissues of adult
275 mammals *in vivo*.

276

277 **Materials and Methods**

278

279 Vector construction

280 Codon-optimized AcrIIC3_{Nme} and AcrIIA4_{Lmo} sequences were ordered as gBlocks (IDT) and amplified
281 using the primers with overhangs to the pCSDest vector by NEBuilder® HiFi DNA Assembly (NEB).
282 Similarly, an mCherry ORF was fused to the C-terminus of each Acr by HiFi DNA assembly (NEB). To
283 insert 3xmiR122 MREs in the 3' UTR of each Acr, top and bottom strands were ordered as oligos (IDT)
284 with restriction sites for SacI and HindIII and annealed before ligating into the vector linearized with the
285 same restriction enzymes. For *in vivo* work, we used the hNme2Cas9-sgRNA_Rosa26 all-in-one AAV
286 vector (Edraki *et al.* 2018). To make scAAV vectors expressing Acr proteins, the original scAAV plasmid
287 encoding an EGFP ORF (a kind gift from J. Xie and G. Gao) and pCSDest-Acr plasmids were digested
288 with SacI and AgeI restriction enzymes and then ligated. The sequences of codon-optimized Acr
289 constructs and miRNA-122 MREs are also provided in the Supplemental Table 1. All plasmids used in
290 this study are summarized in Supplemental Table 2 and will be available on Addgene.

291

292 Cell culture and transfection

293 HEK293T and Huh-7 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented
294 with 10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Gibco). For editing experiments *in*
295 *vitro*, a total of 150 ng of Cas9, 150 ng of sgRNA, and 50 ng of Acr plasmids were transiently transfected
296 in a 24-well format using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. For
297 Western blot analysis, 500 ng of each Acr vector and GFP plasmid used as a transfection control were
298 transfected in a 6-well format using Lipofectamine 2000 (Invitrogen). The total DNA amount was kept
299 constant by adding a stuffer plasmid in all cases.

300

301 Flow cytometry

302 Transfected cells were trypsinized, washed in PBS, and resuspended in PBS for analysis on a
303 MACSQuant® VYB from Miltenyi Biotec. A yellow laser (561 nm) with a 615/20 nm filter and a blue
304 laser (488 nm) with a 525/50 nm filter were used for mCherry and GFP detection, respectively.
305 Subsequent analysis was performed using FlowJo® v10.4.1. Cells were first sorted based on forward and
306 side scattering (FSC-A vs SSC-A), and then single cells were gated using FSC-A and FSC-H. Finally,
307 mCherry-positive cells were recorded after gating for GFP-positive (transfected) cells.

308

309 Western blots

310 Proteins were collected 48 hours post-transfection and their concentrations were measured using the
311 Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Western blots were performed as described
312 previously (Lee *et al.* 2018) with primary mouse anti-FLAG (AbClonal, 1:5000) used for Acr detection
313 and rabbit anti-HSP60 (1:5000) used for a loading control. After incubation with secondary anti-Rabbit
314 or anti-Mouse antibodies (LI-COR IRDye®, 1:20,000), blots were visualized using a LI-COR imaging
315 system.

316

317 Mouse studies

318 C57BL/6 mice were obtained from Jackson Laboratory and all animal maintenance and procedures were
319 performed following the guidelines of the Institutional Animal Care and Use Committee of the University
320 of Massachusetts Medical School. Plasmids for hydrodynamic tail-vein injection were prepared using the
321 EndoFreeMaxi kit (Qiagen). For hydrodynamic liver injection, a total of 90 ug of endotoxin-free plasmids
322 was suspended in 2 ml of injection-grade saline and injected via the tail vein into 8- to 10-week-old
323 C57BL/6 mice. Mice were euthanized 7 days post-injection and liver tissues were collected and stored at
324 -80°C for analyses.

325

326 Indel analysis

327 Genomic DNA from cells or liver tissues were collected using DNeasy Blood & Tissue Kit (Qiagen).
328 Target sites were amplified using High Fidelity 2X PCR Master Mix (NEB). Primers used for PCR are
329 listed in Supplementary Materials. PCR products were purified using DNA Clean & Concentrator Kit
330 (Zymo) and sent for Sanger sequencing to obtain trace files (Genewiz). Indel values were estimated using
331 the TIDE web tool (<https://tide-calculator.nki.nl/>).

332

333 Statistical analysis

334 Standard deviations are derived from each group that has a minimum of three independent replicates
335 unless otherwise noted. Unpaired, two-tailed t-test was used to determine the statistical significance
336 between each group. Resulting P-values < 0.05, 0.01 and 0.001 are indicated by one, two, or three
337 asterisks, respectively.

338

339 Imunohistochemistry

340 Liver tissues were fixed in 4% formalin overnight, paraffin-embedded, and sectioned at the UMass
341 Morphology Core. For Supplemental Figure 2, sectioned slides were stained with H&E for pathology
342 analysis. For IHC, liver sections were dewaxed, rehydrated, and stained following standard protocols
343 previously described (Xue *et al.* 2011) with primary antibodies against 3xHA-tagged Nme2Cas9 (anti-HA;
344 Cell Signaling) and mCherry (anti-RFP; Rockland). Representative images are shown.

345

346 **Author Contributions**

347 J.L. constructed all new plasmids used in this study, conducted all cell culture experiments, and analyzed
348 samples derived from *in vivo* experiments. H.M. and S.Q.L. performed hydrodynamic injection and
349 mouse tissue collection with guidance from W.X. R.I. provided tissue samples from mice injected with
350 AAV8. J.L. and E.J.S. wrote the manuscript and all authors edited the manuscript.

351

352 **Supplemental Materials**

353 Supplemental materials are available for this article.

354

355 **Acknowledgments**

356 We are grateful to Jun Xie, Guangping Gao, and members of the Xue and Sontheimer labs for helpful
357 discussions and sharing resources. We also thank Jordan Smith for assistance with IHC experiments, as
358 well as Kevin Luk, Pengpeng Liu, and Scot Wolfe for sharing sgRNA plasmids. This work was supported
359 by grants from the U.S. National Institutes of Health (GM125797) to E.J.S and (DP2HL137167 and
360 UG3HL147367) to W.X. as well as institutional funds to W.X. and E.J.S.

361

362 **Competing interests**

363 E.J.S. is a co-founder and scientific advisor of Intellia Therapeutics.

364

365 **Figure Legends**

366

367 Figure 1. Overview of Cas9 and microRNA-repressible anti-CRISPR system

368 A. MiRNA-repressible anti-CRISPR and Cas9 editing strategy as designed for use in mice. As an
369 example, miR-122 can be used to achieve liver-specific editing. Upon systemic delivery of Cas9 *in*
370 *vivo* (e.g. via viral vectors), tissues receiving Cas9 and sgRNA potentially result in genome editing;
371 however, co-delivery of miRNA-repressible anti-CRISPR proteins will prevent such editing in
372 non-target tissues that lack miR-122, as depicted in the heart (left). In liver, anti-CRISPR
373 transcripts with perfectly complementary miR-122 binding sites will undergo Ago2-mediated
374 mRNA degradation, and the resulting silencing of the Acr will permit Cas9 editing in the liver
375 (right).

376 B. A schematic of expression vectors for Cas9 orthologs from type II-A (SpyCas9) and II-C
377 (Nme1Cas9 and Nme2Cas9) systems, along with their respective anti-CRISPR proteins,
378 AcrIIA4_{Lmo} and AcrIIC3_{Nme}. The Acr expression constructions were generated with or without
379 three tandem, perfect complementary miRNA-122 binding sites in the 3' UTR. CMV,
380 cytomegalovirus promoter; NLS, nuclear localization signal; AAAA, poly-A tail.

381

382 Figure 2. Validation of miRNA regulation of anti-CRISPR expression in cultured cells

383 (A, B) Hepatocyte-specific silencing of anti-CRISPR expression. Plasmid vectors shown in Fig. 1B
384 encoding either AcrIIC3_{Nme}-mCherry or AcrIIA4_{Lmo}-mCherry, with or without miR-122 MREs,
385 were transfected into (A) human hepatoma (Huh7) cells or (B) non-hepatic HEK293; only the
386 former express miR-122. The expression of mCherry and GFP was visualized by fluorescence
387 microscopy (top) and analyzed by flow cytometry (bottom left). The percentage of mCherry-
388 positive cells in each transfection was normalized to transfection of the control GFP-expressing
389 plasmid. Anti-CRISPR protein expression was also confirmed by western blot against the

390 1xFLAG epitope (bottom right). Heat shock protein 60 (HSP60) was used as a loading control.
391 Scale bar, 400 μ m.

392
393 Figure 3. Hepatocyte-specific genome editing by Nme1Cas9, Nme2Cas9 and SpyCas9 in cultured cells
394 (A-C) HEK293T and Huh7 cells were transiently transfected with plasmids encoding (A)
395 Nme1Cas9 and an sgRNA targeting the *VEGFA* locus, (B) Nme2Cas9 and an sgRNA targeting
396 *LINC01588*, and (C) SpyCas9 and an sgRNA targeting the *BCL11A* enhancer. (A, B) AcrIIC3_{Nme}
397 constructs with or without 3xmiR122BS were co-transfected with the Cas9 and sgRNA constructs
398 as indicated. (C) AcrIIA4_{Lmo} with or without 3xmiR122BS were co-transfected with SpyCas9 and
399 its sgRNA. Data represent mean \pm s.e.m with at least 3 replicates. Editing efficiencies are
400 measured by TIDE.

401
402 Figure 4. Acr inhibition of Nme2Cas9 editing *in vivo*, and release from inhibition by the liver-specific
403 miRNA, miR-122

404 A. Plasmids used for *in vivo* studies to drive the expression of Nme2Cas9/sgRNA and AcrIIC3_{Nme},
405 respectively. U1a, murine promoter; BGH, bovine growth hormone polyA signal; CB-PI,
406 cytomegalovirus-enhancer, chicken β -actin (CB) promoter with SV40-derived mini-intron.
407 B. A schematic of mouse studies. Plasmid vectors shown in (A) are administered into 8- to 10-week-
408 old C56BL/6 mice by hydrodynamic tail vein injection. Liver tissues were collected one week
409 after injection.
410 C. Dose titration of Nme2Cas9/sgRNA plasmid to AcrIIC3_{Nme} plasmid *in vivo*. Percentage of indels
411 at the *Rosa26* target in the livers of C57Bl/6 mice measured by TIDE after hydrodynamic
412 injection of Nme2Cas9/sgRNA and AcrIIC3_{Nme} plasmids at mass ratios of 1:1, 1:1.5, and 1:2.
413 D. Genome editing in the liver by Nme2Cas9 is inhibited by AcrIIC3_{Nme} but restored when
414 AcrIIC3_{Nme}-3xmiR122BS is silenced. Indel percentages at the *Rosa26* locus in the livers of
415 C57Bl/6 mice was measured by TIDE after hydrodynamic injection of Nme2Cas9/sgRNA

416 plasmid, along with anti-CRISPR plasmids with or without 3xmiR122BS. N = 6 mice per group.

417 ns = not significant, p < 0.01 by unpaired, two-tailed t-test.

418

419 **Supplemental Figure Legends**

420

421 Supplemental Figure 1. Editing in different organs collected 50 days after rAAV8 delivery of all-in-one
422 hNme1Cas9/sgRNA targeting *Rosa26* via tail vein injection in C56BL/6 mice (n = 3). Indels are
423 measured by TIDE analysis. Gastr., gastrocnemius muscle.

424

425 Supplemental Figure 2. H&E staining of liver tissue sections from mice injected with hNme2Cas9 and
426 AcrIIC3_{Nme} expression plasmids at different ratios exhibit no overt toxicity. Scale bar, 100 μm.

427

428 Supplemental Figure 3. Immunohistochemistry of liver tissues from mice injected with
429 hNme2Cas9/sgRNA plasmid alone, with AcrIIC3_{Nme} plasmid, or with AcrIIC3_{Nme}-3xmiR122BS, as in
430 Fig. 4D. Anti-mCherry was used to detect mCherry expression from injection control plasmids. Anti-HA
431 was used for 3xHA tagged hNme2Cas9 detection. Control, saline-injected. Scale bar, 100 μm.

432

433 **Supplemental Materials**

434 Table 1. Sequences of codon-optimized anti-CRISPR proteins.

435 Table 2. Plasmids and oligonucleotides used in this study.

436

437

438 **References**

439 Alvarez-Garcia I, Miska EA. 2005. MicroRNA functions in animal development and human disease.

440 *Development* **132**: 4653–4662.

441 Amrani N, Gao XD, Liu P, Edraki A, Mir A, Ibraheim R, Gupta A, Sasaki KE, Wu T, Donohoue PD, et al. 2018. NmeCas9 is an intrinsically high-fidelity genome editing platform. *Genome Biology* **19**: 214.

443 Bartel DP. 2018. Metazoan MicroRNAs. *Cell* **173**: 20–51.

444 Bondy-Denomy J. 2018. Protein Inhibitors of CRISPR-Cas9. *ACS Chem Biol* **13**: 417–423.

445 Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR. 2013. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. *Nature* **493**: 429–432.

447 Bubeck F, Hoffmann MD, Harteveld Z, Aschenbrenner S, Bietz A, Waldhauer MC, Börner K, Fakhiri J, Schmelas C, Dietz L, et al. 2018. Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9. *Nat Methods* **15**: 924–927.

450 Cho SW, Kim S, Kim JM, Kim J-S. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat Biotechnol* **31**: 230–232.

452 Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**: 819–823.

454 Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* **471**: 602.

457 Dong D, Guo M, Wang S, Zhu Y, Wang S, Xiong Z, Yang J, Xu Z, Huang Z. 2017. Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein. *Nature* **546**: 436–439.

459 Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song C-Q, Cao Y, Gallant J, Xue W, Rivera-
460 Pérez JA, et al. 2018. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo
461 Genome Editing. *Mol Cell* **73**:714-726.

462 Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K,
463 Matsuura Y. 2012. Expression of microRNA miR-122 facilitates an efficient replication in
464 nonhepatic cells upon infection with hepatitis C virus. *J Virol* **86**: 7918–7933.

465 Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of Adeno-
466 associated viruses are widely disseminated in human tissues. *J Virol* **78**: 6381–6388.

467 Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P,
468 Magadán AH, Moineau S. 2010. The CRISPR/Cas bacterial immune system cleaves bacteriophage
469 and plasmid DNA. *Nature* **468**: 67–71.

470 Goeckel ME, Basgall EM, Lewis IC, Goetting SC, Yan Y, Halloran M, Finnigan GC. 2019. Modulating
471 CRISPR gene drive activity through nucleocytoplasmic localization of Cas9 in *S. cerevisiae*. *Fungal
472 Biol Biotechnol* **6**: 2.

473 Harrington LB, Doxzen KW, Ma E, Liu J-J, Knott GJ, Edraki A, Garcia B, Amrani N, Chen JS, Cofsky
474 JC, et al. 2017. A Broad-Spectrum Inhibitor of CRISPR-Cas9. *Cell* **170**: 1224–1233.e15.

475 Hinderer C, Katz N, Buza EL, Dyer C, Goode T, Bell P, Richman LK, Wilson JM. 2018. Severe
476 Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an
477 Adeno-Associated Virus Vector Expressing Human SMN. *Hum Gene Ther* **29**: 285–298.

478 Hirosawa M, Fujita Y, Parr CJC, Hayashi K, Kashida S, Hotta A, Woltjen K, Saito H. 2017. Cell-type-
479 specific genome editing with a microRNA-responsive CRISPR-Cas9 switch. *Nucleic Acids Res* **45**:
480 e118.

481 Hoffmann MD, Aschenbrenner S, Grosse S, Rapti K, Domenger C, Fakhiri J, Mastel M, Börner K, Eils
482 R, Grimm D, et al. 2019. Cell-specific CRISPR-Cas9 activation by microRNA-dependent
483 expression of anti-CRISPR proteins. *Nucleic Acids Res.*, ePub ahead of print
484 (<http://dx.doi.org/10.1093/nar/gkz271>).

485 Horak M, Novak J, Bienertova-Vasku J. 2016. Muscle-specific microRNAs in skeletal muscle
486 development. *Dev Biol* **410**: 1–13.

487 Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh J-RJ, Joung JK. 2013.
488 Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol* **31**: 227–229.

489 Hynes AP, Rousseau GM, Agudelo D, Goulet A, Amigues B, Loehr J, Romero DA, Fremaux C, Horvath
490 P, Doyon Y, et al. 2018. Widespread anti-CRISPR proteins in virulent bacteriophages inhibit a
491 range of Cas9 proteins. *Nat Commun* **9**: 2919.

492 Hynes AP, Rousseau GM, Lemay M-L, Horvath P, Romero DA, Fremaux C, Moineau S. 2017. An anti-
493 CRISPR from a virulent streptococcal phage inhibits *Streptococcus pyogenes* Cas9. *Nat Microbiol* **2**:
494 1374–1380.

495 Ibraheim R, Song C-Q, Mir A, Amrani N, Xue W, Sontheimer EJ. 2018. All-in-one adeno-associated
496 virus delivery and genome editing by *Neisseria meningitidis* Cas9 in vivo. *Genome Biol* **19**: 137.

497 Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. 1997. Molecular reconstruction of Sleeping Beauty, a Tc1-
498 like transposon from fish, and its transposition in human cells. *Cell* **91**: 501–510.

499 Jiang J, Zhang L, Zhou X, Chen X, Huang G, Li F, Wang R, Wu N, Yan Y, Tong C, et al. 2016.
500 Induction of site-specific chromosomal translocations in embryonic stem cells by CRISPR/Cas9. *Sci
501 Rep* **6**: 21918.

502 Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A Programmable Dual-

503 RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* **337**: 816–821.

504 Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. 2013. RNA-programmed genome editing in human
505 cells. *Elife* **2**: e00471.

506 Jonas S, Izaurralde E. 2015. Towards a molecular understanding of microRNA-mediated gene silencing.
507 *Nat Rev Genet* **16**: 421–433.

508 Komor AC, Badran AH, Liu DR. 2017. CRISPR-Based Technologies for the Manipulation of
509 Eukaryotic Genomes. *Cell* **169**: 559.

510 Kosicki M, Tomberg K, Bradley A. 2018. Repair of double-strand breaks induced by CRISPR-Cas9
511 leads to large deletions and complex rearrangements. *Nat Biotechnol* **36**: 765–771.

512 Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 2002. Identification of tissue-
513 specific microRNAs from mouse. *Curr Biol* **12**: 735–739.

514 Lee J, Mir A, Edraki A, Garcia B, Amrani N, Lou HE, Gainetdinov I, Pawluk A, Ibraheim R, Gao XD,
515 et al. 2018. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-
516 CRISPR Proteins. *mBio* **9**:e02321-18.

517 Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, et al. 2018. Rescue
518 of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. *Cell* **172**: 979–
519 992.

520 Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han Y-C, Ogrodowski P, Crippa A,
521 Rekhtman N, de Stanchina E, et al. 2014. In vivo engineering of oncogenic chromosomal
522 rearrangements with the CRISPR/Cas9 system. *Nature* **516**: 423–427.

523 Makarova KS, Wolf YI, Koonin EV. 2018. Classification and Nomenclature of CRISPR-Cas Systems:
524 Where from Here? *The CRISPR Journal* **1**: 325–336.

525 Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided
526 human genome engineering via Cas9. *Science* **339**: 823–826.

527 Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, Walton RT, Berry JD, Joung JK,
528 Kleinstiver BP, et al. 2018. Discovery of widespread type I and type V CRISPR-Cas inhibitors.
529 *Science* **362**: 240–242.

530 Marshall R, Maxwell CS, Collins SP, Jacobsen T, Luo ML, Begemann MB, Gray BN, January E, Singer
531 A, He Y, et al. 2018. Rapid and Scalable Characterization of CRISPR Technologies Using an E.
532 *coli* Cell-Free Transcription-Translation System. *Mol Cell* **69**: 146–157.

533 Nakai H, Fuess S, Storm TA, Muramatsu S-I, Nara Y, Kay MA. 2005. Unrestricted hepatocyte
534 transduction with adeno-associated virus serotype 8 vectors in mice. *J Virol* **79**: 214–224.

535 Nakamura M, Srinivasan P, Chavez M, Carter MA, Dominguez AA, La Russa M, Lau MB, Abbott TR,
536 Xu X, Zhao D, et al. 2019. Anti-CRISPR-mediated control of gene editing and synthetic circuits in
537 eukaryotic cells. *Nat Commun* **10**: 194.

538 Pawluk A, Amrani N, Zhang Y, Garcia B, Hidalgo-Reyes Y, Lee J, Edraki A, Shah M, Sontheimer EJ,
539 Maxwell KL, et al. 2016. Naturally Occurring Off-Switches for CRISPR-Cas9. *Cell* **167**: 1829–
540 1838.

541 Rauch BJ, Silvis MR, Hultquist JF, Waters CS, McGregor MJ, Krogan NJ, Bondy-Denomy J. 2017.
542 Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* **168**: 150–158.

543 Senís E, Fatouros C, Große S, Wiedtke E, Niopek D, Mueller A-K, Börner K, Grimm D. 2014.
544 CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
545 *Biotechnol J* **9**: 1402–1412.

546 Shin J, Jiang F, Liu J-J, Bray NL, Rauch BJ, Baik SH, Nogales E, Bondy-Denomy J, Corn JE, Doudna

547 JA. 2017. Disabling Cas9 by an anti-CRISPR DNA mimic. *Sci Adv* **3**: e1701620.

548 van Gent M, Gack MU. 2018. Viral Anti-CRISPR Tactics: No Success without Sacrifice. *Immunity* **49**:

549 391–393.

550 Walther W, Stein U. 1996. Cell type specific and inducible promoters for vectors in gene therapy as an

551 approach for cell targeting. *J Mol Med* **74**: 379–392.

552 Wang X-W, Hu L-F, Hao J, Liao L-Q, Chiu Y-T, Shi M, Wang Y. 2019. A microRNA-inducible

553 CRISPR–Cas9 platform serves as a microRNA sensor and cell-type-specific genome regulation tool.

554 *Nat Cell Biol*. **21**:522-530.

555 Watters KE, Fellmann C, Bai HB, Ren SM, Doudna JA. 2018. Systematic discovery of natural CRISPR–

556 Cas12a inhibitors. *Science* **362**: 236–239.

557 Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, Clement K, Cole MA, Luk K, Baricordi C, et

558 al. 2019. Highly efficient therapeutic gene editing of human hematopoietic stem cells. *Nat Med*, ePub

559 ahead of print (<http://dx.doi.org/10.1038/s41591-019-0401-y>).

560 Xie J, Xie Q, Zhang H, Ameres SL, Hung J-H, Su Q, He R, Mu X, Seher Ahmed S, Park S, et al. 2011.

561 MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene

562 expression. *Mol Ther* **19**: 526–535.

563 Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R,

564 Crowley DG, et al. 2014. CRISPR-mediated direct mutation of cancer genes in the mouse liver.

565 *Nature* **514**: 380–384.

566 Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. 2011. Response and

567 Resistance to NF- B Inhibitors in Mouse Models of Lung Adenocarcinoma. *Cancer Discovery* **1**: 236–

568 247.

569 Yang H, Patel DJ. 2017. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting
570 SpyCas9. *Mol Cell* **67**: 117–127.

571 Zhang G, Budker V, Wolff JA. 1999. High levels of foreign gene expression in hepatocytes after tail vein
572 injections of naked plasmid DNA. *Hum Gene Ther* **10**: 1735–1737.


573 Zhu Y, Gao A, Zhan Q, Wang Y, Feng H, Liu S, Gao G, Serganov A, Gao P. 2019. Diverse Mechanisms
574 of CRISPR-Cas9 Inhibition by Type IIC Anti-CRISPR Proteins. *Mol Cell*. **74**:296-309.

575 Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. 2008. Analysis of AAV serotypes 1-9 mediated gene
576 expression and tropism in mice after systemic injection. *Mol Ther* **16**: 1073–1080.

577

Figure 1

A



B




Figure 2





Figure 3


A

Nme1Cas9



B

Nme2Cas9



C

SpyCas9






Figure 4


A




B




C




D




Supplemental Figure 1



Supplemental Figure 2



Supplemental Figure 3



scale bar 100 um

Supplemental Table 1. Sequences of codon-optimized anti-CRISPR proteins.

AcrIIC3_{Nme}	ATGTTCAAACGGGCCATTATTTCACCGCTTCAACGGCTTCAGAAGGTCACTCGCACGGAAAAACGGCGCCTT GCCAAGATAATTAAACGCCAGAGTTAGTATAATCGACGAGTATCTCGCGCCAAAGACACCAACGCCCTCTGGAC GGACAGTATAGAGCATTCTTTCAATGATGAGTCACCAGCGATGACCGAATTCTCGCTAAGCTCAAGGCCTTC GCAGAAAGCTGACTGGTATAAGCATTGATGCGTGGGAGATTGAAGAGAGCGAGTATGTCATTGCCGTCGAA CGGAGAGATTCCTTGCGGCGCCAATGGCAAAGAAATTTCAAAATT
AcrIIA4_{Lmo}	ATGAACATCAATGATCTGATTAGAGAAATAAGAATAAGACTATACTGTTAAATTGTCCTGAACTGACAGTAAT AGCATAACCCAACTCATCATCAGGGTTAATAATGATGGTAACGAATATGTTATAAGTGAGTCCGAGAACGAATCT ATCGTCGAGAAGTTCATCAGTGCCTTCAAAACGGATGGAACCAAGAGTACGAGGATGAGGAGGAATTTCACAT GATATGCAAACAACTCACTGAAGAGCGAGCTAAC

Supplemental Table 2. Plasmids and oligonucleotides used in this study.

Plasmids used in this study	Source		
peJS1146-pCSDest-AcrIIC3Nme-mCherry	This study		
peJS1147-pCSDest-AcrIIC3Nme-mCherry-miR122BS	This study		
peJS1148-pCSDest-AcrIIA4-mCherry	This study		
peJS1149-pCSDest-AcrIIA4-mCherry-miR122BS	This study		
peJS956-AAV.U1a.hNme2Cas9.Rosa26	Addgene #119924		
peJS804-pscAAV-CB-PI-co.op.AcrIIC3Nme-FLAG-NLS	This study		
peJS828-pscAAV-CB-PI-co.op.AcrIIC3Nme-FLAG-NLS-miR122BS	This study		
peJS789-pscAAV-CB-PI-EGFP	Gao lab		
peJS1173-pLKO.1Spy sgRNA-BCL11A	Wolfe lab		
peJS504-pLKO.1 Nme SgRNA-NTS33	Sontheimer lab		
peJS1155-pLKO.1-Nme2-sgRNA-DeTS6	Sontheimer lab		
TIDE primers			
Target site	Spacer sequence	Forward primer	Reverse primer
Nme1Cas9_VEGFA	GCGGGGAGAAGGCCAGGGGTCACT	GTGTGCAGACGGCAGTCACTAGG	CGTTCCCTCTTGCTAGGAATATTGAAG
Nme2Cas9_LINC01588	GCCTCCCTGCAGGGCTGCTCCC	AGAGGAGCCTCTGACTGCTGCAGA	AGGTCCCTGGCCTTGCCTTCGA
SpyCas9_BCL11A	CTAACAGTTGCTTTATCAC	CTCCATCACCAAGAGAGGCCTTC	TGTGCATAAGTAAGAGCAGATAGC
Nme2Cas9_Rosa26	CTCCCAGGCCAGGGCGGTCTCA	TCAGTTGGCTGTTGGAG	TAGGGGTTGGATAAGCCAGT
Oligonucleotides used for cloning 3xmiR-122BS			
Top strand	AGCTTGACAAACACCATTGTCACACTCCAACAAACACCATTGTCACACTCCAACAAACACCATTGTCACACTCCACCATAGAGCT		
Bottom strand	CTATGGTGGAGTGTGACAATGGTGTGAGTGTGACAATGGTGTGAGTGTGACAATGGTGTGAGTGTGACAATGGTGTGTTGTCA		